文献速递糖尿病肥胖与代谢综合征

利拉鲁肽与主要心血管事件风险的丹麦和瑞典注册队列研究

Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
PubMed 文献 · Lancet Diabetes Endocrinol · 2018-12-05

BACKGROUND: Trial evidence shows that the glucagon-like peptide-1 receptor agonist liraglutide significantly reduces the risk of major cardiovascular events among patients with type 2 diabetes who have established cardiovascular disease or are at high cardiovascular risk.…

要点

  • 利拉鲁肽还降低心血管死亡和全因死亡风险。

核心结论

  • 在大型斯堪的纳维亚队列中,利拉鲁肽相比DPP-4抑制剂与主要心血管事件风险显著降低相关。
  • 有心血管疾病史的患者似乎从利拉鲁肽治疗中获益最大。

临床怎么用

  • 在常规临床实践中,对2型糖尿病且基线使用二甲双胍的患者,利拉鲁肽可考虑用于降低主要心血管事件风险。
  • 有心血管疾病史的患者可能从利拉鲁肽治疗中获得更大心血管获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trial evidence shows that the glucagon-like peptide-1 receptor agonist liraglutide significantly reduces the risk of major cardiovascular events among patients with type 2 diabetes who have established cardiovascular disease or are at high cardiovascular risk. We aimed to assess the cardiovascular effectiveness of liraglutide in routine clinical practice. METHODS: We used data from nationwide registers in Denmark and Sweden for the period from Jan 1, 2010, to Dec 31, 2016, to investigate the risk of major cardiovascular events associated with use of liraglutide, compared with an active comparator drug class, dipeptidyl peptidase-4 (DPP-4) inhibitors, in patients with type 2 diabetes. The cohort included incident users of liraglutide or DPP-4 inhibitors, who were also using metformin at baseline, matched 1:1 on age, sex, and propensity score. The main outcome was major cardiovascular events, a composite outcome consisting of myocardial infarction, stroke, and cardiovascular death. Other outcomes assessed were the individual components of the main composite outcome, heart failure, death from any cause, and an expanded composite major cardiovascular events outcome that also included other ischaemic heart disease, coronary revascularisation, and peripheral arterial disease. FINDINGS: The study population consisted of 23 402 users of liraglutide and 23 402 matched users of DPP-4 inhibitors; patients were followed up for a mean of 3·3 years (SD 2·0). A major cardiovascular event occurred in 1132 users of liraglutide (incidence rate 14·0 per 1000 person-years) and in 1141 users of DPP-4 inhibitors (15·4 per 1000 person-years; hazard ratio [HR] 0·90, 95% CI 0·83-0·98). The HRs were 0·81 (0·71-0·92) for patients with a history of major cardiovascular disease and 0·96 (0·86-1·06) for patients without such a history (p=0·057 [test of homogeneity], suggesting no statistical evidence of heterogeneity). Compared with use of DPP-4 inhibitors, use of liraglutide was associated with a significantly lower risk of cardiovascular death (HR 0·78, 95% CI 0·68-0·91), but no significant differences were identified for risk of myocardial infarction (0·94, 0·84-1·06) or stroke (0·88, 0·77-1·01). Furthermore, use of liraglutide was associated with a significantly lower risk of death from any cause (HR 0·83, 95% CI 0·77-0·90), but no significant differences were identified for risk of heart failure (0·90, 0·80-1·03) or for the expanded major cardiovascular events outcome (0·95, 0·89-1·01). INTERPRETATION: In this large Scandinavian cohort, use of liraglutide, as compared with use of DPP-4 inhibitors, was associated with significantly reduced risk of major cardiovascular events. Patients with history of cardiovascular disease seemed to derive the largest benefit from treatment with liraglutide. These data provide support for the cardiovascular effectiveness of liraglutide in routine clinical practice. FUNDING: Swedish Heart-Lung Foundation, Novo Nordisk Foundation, and Swedish Society for Medical Research.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Svanström H, Ueda P, Melbye M, et al. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes Endocrinol. 2018. PMID: 30527909. doi:10.1016/S2213-8587(18)30320-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。